期刊文献+

间歇性高容量血液滤过对肾替代治疗病人血清莫西沙星药物浓度的影响 被引量:5

Effects of pulse high-volume hemofiltration on serum concentration of moxifloxacin in patients with continuous renal replacement therapy
下载PDF
导出
摘要 目的:研究间歇性高容量血液滤过(PHVHF)治疗时莫西沙星的血清药物浓度变化,为临床用药提供依据。方法:8名行PHVHF治疗患者在治疗开始60 min内匀速静滴莫西沙星400 mg,给药后不同时间收集滤器前、后血样和置换液,采用高效液相色谱法(HPLC)测定血清及置换液中莫西沙星浓度。用DAS 2.1.1软件计算药代动力学参数。结果:PHVHF治疗前后血尿素氮(BUN)及肌酐(SCr)、血清钾(K+)水平显著下降(P<0.05),血清钠(Na+)氯(Cl-)维持稳定。HPLC分析方法测定血滤患者血清及置换液中莫西沙星浓度,线性关系良好,准确度及精密度高。静滴莫西沙星400 mg后在该患者体内的药代动力学符合开放型二室模型。主要药代参数:峰浓度(Cmax)=(4.843±1.854)mg/L,半衰期(T1/2)=(4.822±2.126)h,达峰时间(Tmax)=(1.31±0.59)h,总体分布容积(Vd)=(82.63±24.69)L,总体清除率(CLtot)=(14.36±8.43)L/h,AUC/MIC90在MIC90值分别为0.25 mg/L、0.12 mg/L、0.03 mg/L时均大于100,Cmax/MIC90在MIC90值分别为0.25 mg/L、0.12 mg/L、0.03 mg/L时均大于10。结论:PHVHF治疗可明显改善肾功能,稳定内环境,部分清除血清中莫西沙星,但PHVHF治疗后血清药物浓度仍可达到针对病原菌的有效治疗浓度。 AIM: To study the changes of the serum moxifloxacin concentration in the patients with continuous renal replacement therapy when applied for pulse high-volume hemofiltration(PHVHF).METHODS: The patients applied for PHVHF were intravenously given moxifloxacin at the dose of 400 mg in 60 min.Blood samples were collected from the arterial(input) and venous(output) lines of the extracorporeal circuit immediately at different time points after the beginning of infusion,and replacement fluid was taken at the corresponding time points.The serum concentration of moxifloxacin was measured by high-performance liquid chromatography(HPLC).The pharmacokinetics parameters were determined using DAS 2.1.1 software.RESULTS: Two-compartment model was used to achieve the best concentration-time relation of moxifloxacin.The levels of blood urea nitrogen(BUN),serum creatinine(SCr) and serum K+ were obviously decreased after application of PHVHF(P0.05).The peak serum concentration(Cmax) of moxifloxacin was(4.843±1.854) mg/L.The half-life(T1/2) was(4.822±2.126) h and the peak time(Tmax) was(1.31±0.59) h.The total volume of distribution(Vd) was(82.63±24.69) L.The total clearance(CLtot) was(14.36±8.43) L/h.All the ratios of area under the concentration-time curve(AUC) to 90% minimal inhibitory concentration(MIC90) were more than 100 when the values of MIC90 were 0.25 mg/L,0.12 mg/L and 0.03 mg/L.All the values of Cmax/MIC90 were more than 10 when the values of MIC90 were 0.25 mg/L,0.12 mg/L and 0.03 mg/L.CONCLUSION: Application of PHVHF obviously improves the renal functions and eliminates a part of moxifloxacin in the serum.However,the serum concentration of moxifloxacin remains at the effective level for controlling the pathogenic bacteria.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2011年第5期1008-1011,共4页 Chinese Journal of Pathophysiology
关键词 间歇性高容量血液滤过 莫西沙星 肾替代治疗 Pulse high-volume hemofiltration Moxifloxacin Renal replacement therapy
  • 相关文献

参考文献9

  • 1季大玺,谢红浪,黎磊石.连续性血液净化与非肾脏疾病[J].中国危重病急救医学,2001,13(1):5-9. 被引量:155
  • 2Mouton JW,Dudley MN,Cars O,et al.Standardization of pharmacokinetic pharmacodynamic (PK/PD) terminology for anti-infective drugs:an update[J].J Antimicrob Chemother,2005,55(5):601-607.
  • 3Krasemann C,Meyer J,Tillotson G,et al.Evaluation of the clinical microbiology profile of moxifloxacin[J].Clin Infect Dis,2001,32(3):S51-S63.
  • 4Romero CM,Downey P,Hernandez G.High volume hemofiltration in septic shock[J].Med Intensiva,2010,34(5):345-352.
  • 5Renco C,Bellomo R,Homel P,et al.Effect of different doses in continuous veno-venous hemofiltration on outcoms of acute renal failure:a prospective randomised trial[J].Lancet,2000,356(9223):26-30.
  • 6Nightingale CH.Moxifloxacin,a new antibiotic designed to treat community-acquired respiratory tract infections:a review of microbiologic and pharmacokinetic pharmacodynamic characteristics[J].Pharmacotherapy,2000,20(3):245-256.
  • 7Aminimanizani A,Beringer P,Jelliffe R.Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials[J].Clin Pharmacokinet,2001,40(3):169-187.
  • 8Waqner RS,Granet DB,Lichtenstein SJ,et al.Kinetics of kill of bacterial conjunctivitis isolates with moxifloxacin,a fluoroquinolone,compared with the aminoglycosides tobramycin and gentamicin[J].Clin Ophthalmol,2010,4:41-45.
  • 9Deshpande D,Srivastava S,Meek C,et al.Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection[J].Antimicrob Aqents Chemother,2010,54(6):2534-2539.

共引文献154

同被引文献75

  • 1宋玉果.连续性血液净化对炎性介质清除作用的meta分析[J].中国血液净化,2006,5(1):33-37. 被引量:23
  • 2张震环,李维勤,王浩,燕晓雯,黎介寿.早期持续高容量血滤对SAP猪的胰腺及胰腺外器官病理变化的影响[J].世界华人消化杂志,2006,14(22):2180-2185. 被引量:11
  • 3谢红浪,季大玺,龚德华,徐斌,陶静,陈月梅,任冰,王华,刘志红,黎磊石.连续性血液净化治疗危重患者的疗效分析[J].肾脏病与透析肾移植杂志,2007,16(4):301-307. 被引量:66
  • 4Walsh CR. Multiple organ dysfunction syndrome aider multiple trauma[J]. Orthop Nurs, 2005, 24(5): 324-333; quiz 334-335.
  • 5Bagshaw SM, Uchino S, Bellomo R, et al. Septic aeute kidney injury in critically ill patients: clinical characteristics and outcomes[J]. Clin J Am Soc Nephrol, 2007, 2(3): 431-439.
  • 6Marshall JC. SIRS and MODS: what is their relevance to the science and practice of intensive care?[J]. Shock, 2000, 14(6): 586-589.
  • 7Bone RCj Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process[J]. Chest, 1997, 112(1): 235-243.
  • 8Ronco C, Tetra C, Mariano F, et al. Interpreting the mechanisms of continuous renal replaeemant therapy in sepsis: the peak concentration hypothesis[J]. Artif Organs, 2003, 27(9): 792-801.
  • 9Brunet S, Leblanc M, Geadah D, et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates[J]. Am J Kidney Dis, 1999, 34(3): 486-492.
  • 10Hofmann CL, Fissell WH. Middle-molecule clearance at 20 and 35 ml/kg/h in continuous venovenous hemodiafiltration[J]. Blood Purif, 2010, 29(3): 259-263.

引证文献5

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部